Animal model of sclerotic skin induced by bleomycin: a clue to the pathogenesis of and therapy for scleroderma?
Yamamoto
Toshiyuki
T
Department of Dermatology, Tokyo Medical and Dental University, School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. yamamoto.derm@med.tmd.ac.jp
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects*; D004195:Disease Models, Animal; D007371:Interferon-gamma / Q000276:immunology / Q000627:therapeutic use; D007378:Interleukins / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D012594:Scleroderma, Localized / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D012867:Skin / Q000187:drug effects / Q000276:immunology* / Q000473:pathology*; D016212:Transforming Growth Factor beta / Q000276:immunology / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D007378:Interleukins; D016212:Transforming Growth Factor beta; D001761:Bleomycin; D007371:Interferon-gamma